Shree Ganesh Remedies Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Shree Ganesh Remedies Ltd trades at ₹660, in a confirmed uptrend and 15 weeks into that stage. That is +14.6% against its own 200-day average. It sits at 84% of a 52-week range of ₹423 to ₹707. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 16 straight weeks.

Today the stock is in a confirmed uptrend — week 15 of stage 2, confirmed. At ₹660 it trades +14.6% versus its 200-day average and sits at 84% of its 52-week range (₹423–₹707).

Against the market, two honest reads. Cumulative: over the last 8.9 years the stock moved +2,596% while the NIFTY 500 moved +155% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 16 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Shree Ganesh Remedies Ltd trades at 54.8× P/E, at the pricey end of its own range (85th percentile). Its long-run median P/E is 35.1×, measured across 6.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 54.8× is at the pricey end of its own range (85th percentile), against a long-run median of 35.1× measured over 6.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved −23.0% against a +17.4% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +15.7%/yr price move, ~+8.0%/yr came from earnings growth and ~+7.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 13 June 2026 price, Shree Ganesh Remedies Ltd was paying for profit growth of about 20.9% a year. Profit itself has compounded 33.5% a year over the past 10 years. Today the market pays 54.8× P/E, the 85th percentile of its own 6-year range.

What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Shree Ganesh Remedies Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −8.7% latest against +61.9% at its 12-quarter best), ROCE slipping at 14.0%. The read is built from 11 quarters across 4 curves, on partial evidence.

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

41.1/100 — rank 15 of 20 in Chemicals - Organic · 76% evidence confidence

Shree Ganesh Remedies Ltd scores 41.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 15. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 6.6 + 14.6 + 7.1 + 12.8 = 41.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Shree Ganesh Remedies Ltd reported ₹14.4 Cr of revenue in the Jun 26 quarter, −41.8% year on year. Over 10 years it has compounded at 21.2% a year. The last full year, FY26, came in at ₹109 Cr. The last four reported quarters add to ₹99.0 Cr.

FY26 revenue came in at ₹109 Cr (+0.0% on the year), capping 10 years at 21.2% compound. The latest quarter (Jun 26) printed ₹14.4 Cr, −41.8% year on year.

Pace check: the last four quarters averaged −8.5% growth against the decade's 21.2% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −8.7% over the last 4 quarters against −10.5%/yr over the last 8 — stabilising; TTM profit −29.4% vs −26.5%/yr — stabilising.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Shree Ganesh Remedies Ltd's operating margin is 23.3% in the Jun 26 quarter, −6.3 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0% to 36.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 23.3%, −6.3 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0%–36.0%.

🚨 Why the margin moved: operating margin went −6.3 pp year on year while gross margin went +20.8 pp — the loss came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Shree Ganesh Remedies Ltd earned ₹1.1 Cr of net profit in the Jun 26 quarter, −67.5% year on year. Full-year FY26 profit was ₹18.0 Cr. The 10-year compound rate is 33.5%. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned ₹3.5 Cr.

Jun 26 profit was ₹1.1 Cr, −67.5% year on year. On the full year, FY26 printed ₹18.0 Cr (−21.7%), and the 10-year compound rate is 33.5%.

🚨 Why profit moved: revenue contributed −41.8% and the margin −6.3 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −34.5% vs revenue −8.5%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 123% of Shree Ganesh Remedies Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹24.0 Cr of operating cash against ₹18.0 Cr of profit. After ₹24.0 Cr of capital spending, ₹0.0 Cr was left as free cash.

FY26: operating cash of ₹24.0 Cr against reported profit of ₹18.0 Cr, leaving free cash of ₹0.0 Cr after ₹24.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 123% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 123%: the cash cycle stretched 31 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 2.7× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Shree Ganesh Remedies Ltd's cash conversion cycle runs 236 days in FY26, up from 205 days in FY21. Capital spending ran ₹71.0 Cr over the last 3 years. At FY26 sales of ₹109 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹70.0 Cr sits inside the business at any moment.

FY26: debtors at 109 days, inventory at 209 days — roughly 6.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 236 days, looser than FY21's 205.

The full loop: cash goes out to suppliers and production on day 0; stock waits 209 days to sell; customers pay about 109 days after that; and suppliers themselves are paid at 82 days — netting out to the 236-day cycle.

In money terms: at FY26 sales of ₹109 Cr, each day of the cycle holds about ₹0.3 Cr — so the 236-day loop keeps roughly ₹70.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹71.0 Cr over the last 3 fiscal years against ₹26.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹13.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Shree Ganesh Remedies Ltd earns a ROCE of 14% in FY26. That is up from a trough of 12% in FY16. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 16.5% net margin on 0.52× asset turns.

FY26 ROCE is 14%, recovered from a FY16 trough of 12% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 16.5% net margin × 0.52× asset turns × 1.28× balance-sheet leverage ≈ 11.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Shree Ganesh Remedies Ltd carries ₹31.0 Cr of borrowings against ₹163 Cr of equity in FY26, a debt-to-equity of 0.19. Operating profit covers the interest bill 9×. Over 5 years borrowings went from ₹0.0 Cr to ₹31.0 Cr. Capital spending ran ₹71.0 Cr across the last 3 of those years.

FY26: borrowings of ₹31.0 Cr against equity of ₹163 Cr — a debt-to-equity of 0.19. Operating profit covers the interest bill 9×. Over 5 years borrowings went from ₹0.0 Cr to ₹31.0 Cr while capital spending ran ₹71.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters added 3.5 points of Shree Ganesh Remedies Ltd over 8 quarters, the biggest move on the register. That takes promoters to 72.8% of the company. Domestic institutions moved +0.5 points over the same window, to 0.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +3.5 points over 8 quarters to 72.8%; Domestic institutions: +0.5 points over 8 quarters to 0.5%; Foreign institutions: +0.0 points over 8 quarters to 0.0%.

Why the register moved: promoters drove it (+3.5 points), alongside domestic institutions (+0.5 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Shree Ganesh Remedies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions